87 related articles for article (PubMed ID: 2604292)
21. Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters.
Disis ML; McDonald TL; Colombo JL; Kobayashi RH; Angle CR; Murray S
Pediatr Res; 1986 May; 20(5):385-90. PubMed ID: 3714348
[TBL] [Abstract][Full Text] [Related]
22. Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection.
Moss RB
Chest; 1987 Apr; 91(4):522-6. PubMed ID: 3829744
[TBL] [Abstract][Full Text] [Related]
23. Identification of material with paternal HLA antigen immunoreactivity from purported circulating immune complexes in patients with gestational trophoblastic neoplasia.
Lahey SJ; Steele G; Berkowitz R; Rodrick ML; Ross DS; Goldstein DP; Zamcheck N; Wilson RE; Deasy JM
J Natl Cancer Inst; 1984 May; 72(5):983-90. PubMed ID: 6325794
[TBL] [Abstract][Full Text] [Related]
24. Immune complexes and complement abnormalities in patients with cystic fibrosis. Increased mortality associated with circulating immune complexes and decreased function of the alternative complement pathway.
Wisnieski JJ; Todd EW; Fuller RK; Jones PK; Dearborn DG; Boat TF; Naff GB
Am Rev Respir Dis; 1985 Oct; 132(4):770-6. PubMed ID: 3850731
[TBL] [Abstract][Full Text] [Related]
25. [Clinical significance of specific features of HLA antigen incidence in patients with mucoviscidosis and in their relatives].
Gembitskaia TE; Kocharian RKh; Petrova MA
Vestn Ross Akad Med Nauk; 1996; (3):41-4. PubMed ID: 8672961
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometric analysis of HLA-DR antigen in conjunctival epithelial cells of patients with cystic fibrosis.
Mrugacz M; Zak J; Bakunowicz-Lazarczyk A; Wysocka J; Minarowska A
Eye (Lond); 2007 Aug; 21(8):1062-6. PubMed ID: 16710427
[TBL] [Abstract][Full Text] [Related]
27. [HLA antigens, complement types, and amebic liver abscess in Mexican mestizos].
Arellano J; Granados J; Pérez E; Félix C; Kretschmer RR
Arch Invest Med (Mex); 1990; 21 Suppl 1():11-4. PubMed ID: 2136473
[TBL] [Abstract][Full Text] [Related]
28. [Study of genetic markers in families of patients with tuberculosis].
Rakhimov AKh; Pospelov LE
Probl Tuberk; 1990; (9):7-8. PubMed ID: 2274516
[TBL] [Abstract][Full Text] [Related]
29. Demonstration of neutrophil dysfunction in the serum of patients with cystic fibrosis.
Holland EJ; Loren AB; Scott PJ; Niwa Y; Yokoyama MM
J Clin Lab Immunol; 1981 Sep; 6(2):137-9. PubMed ID: 7288870
[TBL] [Abstract][Full Text] [Related]
30. HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype.
Aron Y; Polla BS; Bienvenu T; Dall'ava J; Dusser D; Hubert D
Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1464-8. PubMed ID: 10228112
[TBL] [Abstract][Full Text] [Related]
31. HLA-DR2 predicts susceptibility and disease chronicity in Irish sarcoidosis patients.
Rutherford RM; Brutsche MH; Kearns M; Bourke M; Stevens F; Gilmartin JJ
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Oct; 21(3):191-8. PubMed ID: 15554075
[TBL] [Abstract][Full Text] [Related]
32. [Circulating immunocomplexes in patients with cystic fibrosis].
Pavluchová J; Tomásová H; Vávrová V
Cesk Pediatr; 1984 Dec; 39(12):709-13. PubMed ID: 6440714
[No Abstract] [Full Text] [Related]
33. [Serum beta 2-microglobulin and HLA alloantigens in primary Gougerot-Sjögren syndrome. A possible relation with HLA-DR3 specificity].
Bianucci G; Campana G; Maddali-Bongi S; D'Agata A; Pradella F; Colafranceschi M; Castagnoli A
Rev Rhum Mal Osteoartic; 1991 May; 58(5):339-42. PubMed ID: 1711713
[TBL] [Abstract][Full Text] [Related]
34. HLA type, islet cell antibodies, and glucose intolerance in cystic fibrosis.
Stutchfield PR; O'Halloran SM; Smith CS; Woodrow JC; Bottazzo GF; Heaf D
Arch Dis Child; 1988 Oct; 63(10):1234-9. PubMed ID: 3058046
[TBL] [Abstract][Full Text] [Related]
35. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles.
Steere AC; Dwyer E; Winchester R
N Engl J Med; 1990 Jul; 323(4):219-23. PubMed ID: 2078208
[TBL] [Abstract][Full Text] [Related]
36. Type 1 diabetes in the Spanish population: additional factors to class II HLA-DR3 and -DR4.
Urcelay E; Santiago JL; de la Calle H; Martínez A; Méndez J; Ibarra JM; Maluenda C; Fernández-Arquero M; de la Concha EG
BMC Genomics; 2005 Apr; 6():56. PubMed ID: 15842729
[TBL] [Abstract][Full Text] [Related]
37. Allergy in patients with cystic fibrosis.
Yohe RM
Ann Allergy; 1972 Nov; 30(11):627-31. PubMed ID: 5080739
[No Abstract] [Full Text] [Related]
38. HLA-DR2 antigen linkage in patients with apical hypertrophic cardiomyopathy in Japan.
Kishimoto C; Takada H; Hiraoka Y; Suzaki M; Maruya E; Tomioka N
Cardiology; 1996; 87(6):488-91. PubMed ID: 8904675
[TBL] [Abstract][Full Text] [Related]
39. Immune complexes in cystic fibrosis.
McFarlane H; Holzel A; Brenchley P; Allan JD; Wallwork JC; Singer BE; Worsley B
Br Med J; 1975 Feb; 1(5955):423-8. PubMed ID: 1090336
[TBL] [Abstract][Full Text] [Related]
40. Immunogenetic susceptibility for post-schistosomal hepatic fibrosis.
Hafez M; Aboul Hassan S; el-Tahan H; el-Shennawy F; Khashaba M; al-Tonbary Y; el-Morsi Z; el-Sallab S; el-Desoky I; el-Shazly A
Am J Trop Med Hyg; 1991 Apr; 44(4):424-33. PubMed ID: 1904196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
